9/19/2019 8:09:16 AM
Xeris Pharma Begins Dosing Patients In Phase 2 Clinical Trial Of Novel Fixed-Ratio Co-Formulation Of Pramlintide-Insulin
6/27/2019 8:05:05 AM
Xeris Doses First Subject In Phase 2 Trial With Ready-to-use Glucagon
6/6/2019 4:12:36 PM
Xeris Pharmaceuticals Trading Expected To Resume At 4:30 PM ET
6/6/2019 4:03:41 PM
Xeris Pharmaceuticals Trading Halted; Pending News
2/13/2019 7:54:24 PM
Xeris Prices Public Offering Of 5.88 Mln Shares At $10.00/shr
12/20/2018 8:33:25 AM
EMA Grants Orphan Drug Designation For Xeris’ Investigational Ready-to-Use Glucagon For Treatment Of NIPHS
11/7/2018 8:15:09 AM
Xeris Pharmaceuticals Q3 Net Loss Widens To $14.8 Mln From $7.5 Mln Last Year
10/23/2018 8:35:57 AM
Xeris Pharma Announces FDA Acceptance For Review Of NDA For Ready-to-Use Glucagon Rescue Pen
8/17/2018 8:31:16 AM
Xeris Pharma And OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon
8/13/2018 8:16:23 AM
Xeris Pharma Q2 Net Loss Of $13.0 Mln Or $3.07/Shr Vs $5.2 Mln Or $2.59/Shr Last Year